zur Navigation zum Inhalt




Cancer is a major global public health problem and despite considerable advances in disease awareness, diagnosis and treatment, it remains an area of significant unmet medical need. Boehringer Ingelheim has a long-term commitment to deliver tomorrow’s cancer therapies by discovering and developing novel treatment options that combine ground-breaking science with high therapeutic value for patients.


The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.


Afatinib is an irreversible ErbB Family Blocker approved in over 40 countries worldwide including the EU, US, Japan, Taiwan, Canada and Mexico. It is indicated for the treatment of patients with distinct types of Epidermal Growth Factor Receptor (EGFR) mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), a specific type of lung cancer. It is an oral, once daily targeted therapy.


Nintedanib is a triple angiokinase inhibitor which targets the three key receptors involved in angiogenesis and tumour growth. Nintedanib in combination with docetaxel is approved in the European Union (EU) for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.


Oncology on YouTube

This Oncology Channel features informative videos on lung, ovarian, head & neck and breast cancer to raise awareness and provide useful information on the latest research and development in these areas.

CSCO (Chinese Society of Clinical Oncology)

The Chinese Society of Clinical Oncology (CSCO) is a public professional academic group that is voluntarily constituted by clinical oncology professionals, relevant enterprises and public institutions. CSCO has been committed to developing the Continuing Medical Education on clinical oncology, enhancing multi-discipline collaboration, encouraging multi-center research, promoting the standardization of tumor diagnosis and treatment, furthering the development of clinical oncology, so as to benefit patients in all.







This website is intended only for healthcare professionals outside the US, the UK, Australia and Canada

Available for FREE.

memo SPECIAL ISSUES offer informative,
educational reports from leading inter-
national congresses. Sponsored by
Boehringer Ingelheim and produced by
Springer, this educational resource is
available for free.





a patient case-based
educational tool for


This software tool was specifically developed for oncologists to transfer their individual patient cases into a unified and illustrative format for presentation. Click here




Looking for memo on

click here

Further educational resources

can be found at Boehringer Ingelheim’s dedicated oncology site: inoncology.com